scholarly journals The Prescription Pattern of Chinese Herbal Products ContainingGinsengamong Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Wei-Lung Hsu ◽  
Yueh-Ting Tsai ◽  
Chien-Tung Wu ◽  
Jung-Nien Lai
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Population Based ◽  
Interactive Effects ◽  
Tamoxifen Treatment ◽  
Research Database ◽  
Herbal Products ◽  
Chinese Herbal

Background.The purpose of our study is to analyze the association between prescribed Chinese herbal products (CHPs) containingGinsengand the risk of endometrial cancer among tamoxifen (TMX) users and to identify any possible interactive effects betweenGinsengand TMX with respect to preventing the development of subsequent endometrial cancer in an estrogen-dependent breast cancer population in Taiwan.Methods.All patients newly diagnosed with invasive breast cancer receiving tamoxifen treatment from January 1, 1998, to December 31, 2008, were selected from the National Health Insurance Research Database. The usage, frequency of service, and CHP-Ginsengprescribed across the 30,556 TMX-treated breast cancer (BC) survivors were evaluated. Logistic regression was employed to estimate the odds ratios (ORs) for the utilization of CHP-Ginseng. Cox’s proportional hazard regression was performed to calculate the hazard ratios (HRs) for endometrial cancer associated withGinsenguse among the TMX-treated BC cohort.Results.The HR for the development of endometrial cancer among breast cancer survivors who had ever takenGinsengafter TXM treatment was significantly decreased compared to those who never used CHP.Conclusion.A significant inhibitory relationship betweenGinsengconsumption and subsequent endometrial cancer less than 2 years after TMX treatment was detected among BC survivors.

scholarly journals Concurrent Use in Taiwan of Chinese Herbal Medicine Therapies among Hormone Users Aged 55 Years to 79 Years and Its Association with Breast Cancer Risk: A Population-Based Study

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Yueh-Ting Tsai ◽  
Jung-Nien Lai ◽  
Chien-Tung Wu ◽  
Shun-Ku Lin
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Proportional Hazards ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Research Database ◽  
Herbal Products ◽  
Chinese Herbal ◽  
Concurrent Use

Background. The purpose of the present study was to analyze the concurrent use of Chinese herbal products (CHPs) among women aged 55 to 79 years who had also been prescribed hormonal therapies (HT) and its association with breast cancer risk.Methods. The use, frequency of service, and CHP prescribed among 17,583 HT users were evaluated from a random sample of 1 million beneficiaries from the National Health Insurance Research Database. A logistic regression method was used to identify the factors that were associated with the coprescription of a CHP and HT. Cox proportional hazards regressions were performed to calculate the hazard ratios (HRs) of breast cancer between the TCM nonusers and women who had undergone coadministration of HT and a CHP or CHPs.Results. More than one out of every five study subjects used a CHP concurrently with HT (CHTCHP patients).Shu-Jing-Huo-Xie-Tangwas the most commonly used CHP coadministered with HT. In comparison to HT-alone users, the HRs for invasive breast cancer among CHTCHP patients were not significantly increased either in E-alone group or in mixed regimen group.Conclusions. The coadministration of hormone regimen and CHPs did not increase the risk of breast cancer.

scholarly journals Chinese Herbal Medicine as an Adjunctive Therapy Ameliorated the Incidence of Chronic Hepatitis in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Kuo-Chin Huang ◽  
Hung-Rong Yen ◽  
Jen-Huai Chiang ◽  
Yuan-Chih Su ◽  
Mao-Feng Sun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Chronic Hepatitis ◽  
Cohort Study ◽  
Herbal Medicine ◽  
Incidence Rate ◽  
Chinese Herbal Medicine ◽  
Therapeutic Potential ◽  
Population Based ◽  
Research Database ◽  
Chinese Herbal

We conducted a National Health Insurance Research Database-based Taiwanese nationwide population-based cohort study to evaluate whether Chinese herbal medicine (CHM) treatment decreased the incidence of chronic hepatitis in breast cancer patients receiving chemotherapy and/or radiotherapy. A total of 81171 patients were diagnosed with breast cancer within the defined study period. After randomly equal matching, data from 13856 patients were analyzed. Hazard ratios of incidence rate of chronic hepatitis were used to determine the influence and therapeutic potential of CHM in patients with breast cancer. The patients with breast cancer receiving CHM treatment exhibited a significantly decreased incidence rate of chronic hepatitis even across the stratification of age, CCI score, and treatments. The cumulative incidence of chronic hepatitis for a period of seven years after initial breast cancer diagnosis was also reduced in the patients receiving CHM treatment. The ten most commonly used single herbs and formulas were effective in protecting liver function in patients with breast cancer, where Hedyotis diffusa and Jia-Wei-Xiao-Yao-San were the most commonly used herbal agents. In conclusion, our study provided information that western medicine therapy combined with CHM as an adjuvant modality may have a significant impact on liver protection in patients with breast cancer.

scholarly journals Factors associated with physical inactivity in adult breast cancer survivors-A population-based study

2018 ◽  
Vol 7 (12) ◽  
pp. 6331-6339 ◽  
Author(s):  
Salam A. Huneidi ◽  
Nicole C. Wright ◽  
Arnisha Atkinson ◽  
Smita Bhatia ◽  
Purnima Singh
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Physical Inactivity ◽  
Breast Cancer Survivors ◽  
Population Based ◽  
Population Based Study ◽  
Factors Associated

scholarly journals Comorbidity burden in long‐term breast cancer survivors compared with a cohort of population‐based controls from the MARIE study

Cancer ◽  
2020 ◽  
Author(s):  
Annika Möhl ◽  
Ester Orban ◽  
Audrey Y. Jung ◽  
Sabine Behrens ◽  
Nadia Obi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Population Based ◽  
Comorbidity Burden

Development of second primary cancers in breast cancer survivors.

2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 257-257
Author(s):  
Hong Kyu Jung ◽  
Jihyoun Lee ◽  
Zisun Kim ◽  
Min Hyuk Lee ◽  
Ilkyun Lee
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Thyroid Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Breast Cancer Patients ◽  
Second Primary Cancers

257 Background: Breast cancer survivors have slightly increased risk of second primary cancers. Importance of screening for second cancers has been raised due to increased survival in those populations. Not only having genetic risk such as BRCA mutation, but also treatment-related risk presents. The most common second primary cancer is breast cancer. Colon cancer, uterine cancer, and ovarian cancer showed increased cumulative incidence. In this study, we assessed development second primary cancers in breast cancer survivors. Methods: Medical record of breast cancer patients was reviewed retrospectively in three tertiary medical institutions. Available data of ICD-9 record after breast cancer diagnosis was evaluated. Diagnosis of second primary breast cancer was excluded in evaluation. Results: Since Jan 1989 to Jan 2014, available medical records were reviewed in breast cancer patients(N = 5880) in three institutions(one urban and the other two rural institutions). Cumulative incidence of overall second primary cancers was 4.57%. Among 269 second primary cancers, thyroid cancer(44.2%) was most common second primary cancer, followed by gastric cancer(10.0%). Gastric cancers were more common in rural institution than urban area(14.2 % vs 5.5%), while incidence of thyroid cancer is elevated in urban institution(57.8% vs 31.9%). Among 9 patients who has been diagnosed endometrial cancer, 7 patients had history of selective estrogen receptor modulator(tamoxifen or toremifen) treatment. Development of lung cancer was not related to breast cancer radiation treatment(4 of 15 patients). Leukemia after breast cancer treatment was diagnosed in 5 patients (8.5% of second primary cancers), three of them were adult T cell leukemia and two of them were acute myeloid leukemia. Conclusions: Incidence of cancer in general population was reflected to development of second primary cancer in breast cancer survivors. Endocrine treatment was related increased incidence of endometrial cancer, respectively. Application of personalized cancer screening plan would be important in this patient group.

A Population-based Randomized Controlled Exercise Trial Among Breast Cancer Survivors

2005 ◽  
Vol 37 (Supplement) ◽  
pp. S358???S359
Author(s):  
Marty Alvarez-Reeves ◽  
Lisa Cadmus ◽  
Eileen Mierzejewski ◽  
Cami Cook ◽  
Andrew Wiley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Population Based ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document